
SNTI Stock Forecast & Price Target
SNTI Analyst Ratings
Bulls say
Senti Biosciences Inc. demonstrates a strong positive outlook due to the promising preclinical results of its allogeneic CAR-NK therapies, particularly SENTI-202, which has shown significant anti-tumor activity and improved survival in preclinical models, positioning the company favorably in the oncology market. The engineered NK cells' enhanced safety profile and multi-target capabilities provide a competitive edge over existing therapies, especially with increasing support from regulatory authorities through Orphan Drug Designation (ODD), which facilitates collaboration and accelerates development. Additionally, the focus on durability and the expectation of positive data updates in 4Q25 further bolster confidence in Senti Biosciences' potential to capture substantial market opportunities in an evolving landscape of cell and gene therapies.
Bears say
Senti Biosciences Inc faces several fundamental challenges that contribute to a negative outlook on its stock. Key risks include the potential decline in the clinical complete response (cCR) rate for its lead therapy, SENTI-202, due to the aggressive nature of acute myeloid leukemia (AML), alongside broader concerns regarding safety signals and efficacy outcomes in clinical trials. Furthermore, the company's market capitalization of approximately $47 million is notably lower than that of its competitors, indicating a lack of investor confidence that may be exacerbated by anticipated financing needs and a limited cash runway extending into late 2025, raising concerns about the company’s future viability and competitive positioning in the biotechnology sector.
This aggregate rating is based on analysts' research of Senti Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SNTI Analyst Forecast & Price Prediction
Start investing in SNTI
Order type
Buy in
Order amount
Est. shares
0 shares